Skip to main content
Home > Week in Review > Clinical Status

Chronological Index of BioCentury, Week in Review: Clinical Status

BioCentury, Week in Review Current Issue
  • ACHN-975: Phase I started

    Achaogen Inc., South San Francisco, Calif. Product: ACHN-975 Business: Infectious Molecular target: UDP-3-O-[3-hydroxymyristoyl] N-acetylglucosamine deacetylase (LpxC) Description: N-acetylglucosamine deacetylase (LpxC)…

    Published on 5/21/2012
  • Aes-103 5-hydroxymethyl-2-furfural: Phase I/IIa started

    AesRx LLC, Newton, Mass. Product: Aes-103 5-hydroxymethyl-2-furfural Business: Hematology Molecular target: Hemoglobin Description: Aromatic aldehyde that increases the affinity of sickle hemoglobin for oxygen …

    Published on 5/21/2012
  • Aggrastat tirofiban: Phase II started

    Iroko Pharmaceuticals LLC, Philadelphia, Pa. Medicure Inc. (TSX-V:MPH; Pink:MCUJ), Winnipeg, Manitoba Merck & Co. Inc. (NYSE:MRK), Whitehouse Station, N.J. Product: Aggrastat tirofiban Business: Cardiovascular Molecular…

    Published on 5/21/2012
  • ALD-401: Phase II ongoing

    Cytomedix Inc. (OTCBB:CMXI), Gaithersburg, Md. Product: ALD-401 Business: Neurology Molecular target: NA Description: Stems cells derived from bone marrow expressing high levels of aldehyde dehydrogenase Indication: …

    Published on 5/21/2012
  • Curcumin: Phase I/II started

    Cancer Research UK, London, U.K. Product: Curcumin Business: Cancer Molecular target: NA Description: Plant extract found in the spice turmeric Indication: Treat colorectal cancer Endpoint: Safety; efficacy as measured …

    Published on 5/21/2012
  • GDC-0068: Phase Ib/II started

    Array BioPharma Inc. (NASDAQ:ARRY), Boulder, Colo. Genentech Inc., South San Francisco, Calif. Roche (SIX:ROG; OTCQX:RHHBY), Basel, Switzerland Product: GDC-0068, RG7440 Business: Cancer Molecular target: Protein kinase…

    Published on 5/21/2012
  • GLPG0634: Phase IIa started

    Galapagos N.V. (Euronext:GLPG; Pink:GLPYY), Mechelen, Belgium Abbott Laboratories (NYSE:ABT), Abbott Park, Ill. Product: GLPG0634 Business: Autoimmune Molecular target: Janus kinase-1 (JAK-1) Description: Janus kinase-1…

    Published on 5/21/2012
  • GM-CT-01: Phase I/II started

    Galectin Therapeutics Inc. (NASDAQ:GALT), Newton, Mass. Product: GM-CT-01 (formerly Davanat) Business: Cancer Molecular target: Galectin-3 (LGALS3); Galectin-1 (LGALS1) Description: Polysaccharide in a carbosome …

    Published on 5/21/2012
  • Inavir laninamivir: Completed Phase III enrollment

    Biota Holdings Ltd. (ASX:BTA), Notting Hill, Australia Daiichi Sankyo Co. Ltd. (Tokyo:4568; Osaka:4568), Tokyo, Japan Product: Inavir laninamivir (CS-8958) Business: Infectious Molecular target: Neuraminidase (NEU1) (…

    Published on 5/21/2012
  • JVS-100: Phase IIa started

    Juventas Therapeutics Inc., Cleveland, Ohio Product: JVS-100 Business: Cardiovascular Molecular target: Stromal cell-derived factor-1 Description: Non-viral DNA plasmid encoding stromal cell-derived factor-1 Indication:…

    Published on 5/21/2012
  • L-DOS47: Phase I/II started

    Helix BioPharma Corp. (TSX:HBP; NYSE-A:HBP), Aurora, Ontario Product: L-DOS47 Business: Cancer Molecular target: Not available Description: Plant-derived urease combined with a highly specialized antibody agent to …

    Published on 5/21/2012
  • Livatag doxorubicin Transdrug: Phase III started

    BioAlliance Pharma S.A. (Euronext:BIO), Paris, France Product: Livatag doxorubicin Transdrug (BA-003) Business: Cancer Molecular target: DNA Description: Nanoparticle formulation of doxorubicin Indication: Treat …

    Published on 5/21/2012
  • Masitinib: Phase III started

    AB Science S.A. (Euronext:AB), Paris, France Product: Masitinib (AB1010) Business: Cancer Molecular target: Stem cell factor (SCF) receptor tyrosine kinase (c-Kit) (KIT)(CD117) Description: Stem cell factor (SCF) …

    Published on 5/21/2012
  • NanoString Breast Cancer Intrinsic Subtyping Assay update

    NanoString Technologies Inc., Seattle, Wash. Product: NanoString Breast Cancer Intrinsic Subtyping Assay Business: Diagnostic Molecular target: NA Description: Breast cancer intrinsic subtyping assay that runs on the …

    Published on 5/21/2012
  • Promethera HepaStem: Phase I/II started

    Promethera Biosciences S.A., Mont-Saint-Guibert, Belgium Product: Promethera HepaStem Business: Endocrine/Metabolic Molecular target: NA Description: Cell therapy of human adult liver-derived mesenchymal stem cells (…

    Published on 5/21/2012
  • Resminostat: Phase I started

    4SC AG (Xetra:VSC), Planegg-Martinsried, Germany Yakult Honsha Co. Ltd. (Tokyo:2267), Tokyo, Japan Product: Resminostat (4SC-201) (formerly BYK408740) Business: Cancer Molecular target: Histone deacetylase (HDAC) …

    Published on 5/21/2012
  • Selumetinib: Phase I started

    Array BioPharma Inc. (NASDAQ:ARRY), Boulder, Colo. AstraZeneca plc (LSE:AZN; NYSE:AZN), London, U.K. Product: Selumetinib (AZD6244, ARRY-886) Business: Cancer Molecular target: MEK Description: Small molecule MEK …

    Published on 5/21/2012
  • Zevalin ibritumomab tiuxetan: Phase II started

    Spectrum Pharmaceuticals Inc. (NASDAQ:SPPI), Henderson, Nev. Bayer AG (Xetra:BAYN), Leverkusen, Germany Product: Zevalin ibritumomab tiuxetan Business: Cancer Molecular target: CD20 Description: Yttrium-90-radiolabeled …

    Published on 5/21/2012
  • 212Pb-TCMC-Trastuzumab: Phase I started

    Areva Med LLC, Bethesda, Md. Product: 212Pb-TCMC-Trastuzumab Business: Cancer Molecular target: NA Description: Trastuzumab combined with lead-212 isotope Indication: Treat cancer that has metastasized the abdominal …

    Published on 5/14/2012
  • ACH-3102: Phase I started

    Achillion Pharmaceuticals Inc. (NASDAQ:ACHN), New Haven, Conn. Product: ACH-3102 Business: Infectious Molecular target: HCV NS5A protein Description: HCV NS5A protein inhibitor Indication: Treat hepatitis C virus (HCV) …

    Published on 5/14/2012
  • Adcetris brentuximab vedotin: Phase III started

    Seattle Genetics Inc. (NASDAQ:SGEN), Bothell, Wash. Takeda Pharmaceutical Co. Ltd. (Tokyo:4502), Osaka, Japan Product: Adcetris brentuximab vedotin (SGN-35) Business: Cancer Molecular target: CD30 Description: Antibody-…

    Published on 5/14/2012
  • ADXS-HPV: Phase I/II started

    Advaxis Inc. (OTCBB:ADXS), North Brunswick, N.J. Product: ADXS-HPV (ADXS11-001) (formerly Lovaxin C) Business: Cancer Molecular target: Not applicable Description: Live Listeria monocytogenes-expressing HPV type 16 E7 …

    Published on 5/14/2012
  • A/H5N1 Avian Influenza Vaccine: Phase I started

    Novavax Inc. (NASDAQ:NVAX), Rockville, Md. Product: A/H5N1 Avian Influenza Vaccine Business: Infectious Molecular target: NA Description: Monovalent virus-like particle (VLP) vaccine containing hemagglutinin (HA), …

    Published on 5/14/2012
  • ALD403: Phase I started

    Alder Biopharmaceuticals Inc., Bothell, Wash. Product: ALD403 Business: Neurology Molecular target: Calcitonin gene-related peptide (CGRP) Description: MAb targeting calcitonin gene-related peptide (CGRP) Indication: …

    Published on 5/14/2012
  • Arikace: Development ongoing

    Insmed Inc. (NASDAQ:INSM), Monmouth Junction, N.J. Product: Arikace (formerly SLIT amikacin) Business: Infectious Molecular target: Ribosomal 30S subunit Description: Sustained-release lipid inhaled targeting (SLIT) …

    Published on 5/14/2012

< Previous   1  2  3  4  5  Next >
Subscribe Now
Free Trial

About BioCentury

Decision-shaping business intelligence for the global biotech and pharma industry since 1993

Log In


Forgot password  |  Forgot Login


If you are a subscriber, but have forgotten or have never received a password, please go here and ask us to send you a new one.

Catalent

Week in Review

The biotech industry's most complete compendium of corporate, clinical and financial transactions provides an efficient surveillance system for:

  • Deals
  • Regulatory Events
  • Clinical Results
  • Financings
  • Management News

Need custom ComputerVision Software?